诊断学理论与实践2024，Vol.23Issue(3)：278-284,7.DOI:10.16150/j.1671-2870.2024.03.005
干燥综合征发病免疫机制研究现状及靶向治疗策略进展
Advances in current research on the immunopathogenesis of Sjögren's syndrome and targeted therapeutic strategies
摘要
Abstract
Sjögren's syndrome(SS)is a prevalent systemic autoimmune disease,primarily affecting exocrine glands,characterized by lymphocyte and plasma cell infiltration.Patients typically exhibit dry mouth and eyes,with potential in-volvement of the digestive tract,lungs,and kidneys.In China,SS prevalence ranges from 0.29%to 0.77%,rising to 3.00%-4.00%among the elderly.In Europe,the prevalence is approximately 0.23%.The pathogenesis of SS involves interactions of multiple cells and cytokines,including salivary gland epithelial cells,T-cells,B-cells,dendritic cells,interferon(IFN),interleukin(IL),tumour necrosis factor(TNF)and inflammasomes.Currently,glandular therapy for SS is primarily lo-calised,while treatment for systemic involvement is mainly borrowed from other autoimmune diseases,with no approved tar-geted drugs yet.Among the targeted therapeutic agents for SS,rituximab,a B-cell targeted therapy,is the most studied and has shown improved salivary efficacy in SS patients with cryoglobulin vasculitis.BAFF inhibitors,CD40 targeting agents,and mesenchymal stem cells have also demonstrated cartain therapeutic effects.For most systemic involvement,glucocorti-coids(GCs)are the first-line treatment,while immunosuppressants and biologics serve as second-line options for GCs-toler-ant or resistant patients.Although many potential therapeutic targets have been identified,few drugs have been clinically translated.Currently,there is a need to develop relatively safe and effective treatment regimens with minimal adverse ef-fects through comprehensive patient assessment and multidisciplinary collaboration.Future SS drug research will focus on targeted therapies,adverse effects reduction,and multi-drug combinations.关键词
干燥综合征/免疫机制/靶向药物Key words
Dry syndrome/Immune mechanism/Targeted drugs分类
医药卫生引用本文复制引用
袁祥,厉小梅..干燥综合征发病免疫机制研究现状及靶向治疗策略进展[J].诊断学理论与实践,2024,23(3):278-284,7.基金项目
国家自然科学基金(U2120365) （U2120365）
"科大新医学"联合基金(WK9110000148) （WK9110000148）
